Hedin K E, Bell M P, Kalli K R, Huntoon C J, Sharp B M, McKean D J
Department of Immunology, Mayo Foundation, Rochester, MN 55905, USA.
J Immunol. 1997 Dec 1;159(11):5431-40.
Recent molecular evidence points to transient and/or stage-specific expression of delta- and kappa-opioid receptors by thymic and peripheral T lymphocytes. Since medical treatments or stress commonly increase opioid levels, it is important to understand the mechanisms by which opioids affect T lymphocyte functions. We therefore created and studied a T cell line expressing the cloned delta-opioid receptor (DOR1). DOR1 ligation by a specific DOR1 agonist, deltorphin, augmented IL-2 secretion by synergizing with signals from TCR-CD3 and CD28. Reporter gene constructs were used to map this effect of deltorphin to the AP-1- and NF-AT/AP-1-binding sites of the IL-2 promoter. Although DOR1 signaling increased [Ca2+]i, deltorphin enhanced transcriptional activity of the NF-AT/AP-1-binding site via a mechanism independent of calcineurin and distinct from the effects of elevated [Ca2+]i. Deltorphin also increased accumulation of AP-1 transcription factor complexes, suggesting that DOR1 augments IL-2 secretion by increasing the AP-1 component of the NF-AT/AP-1 transcription factor. These results advance the molecular understanding of opioid effects on lymphocytes, and in addition, demonstrate regulation of IL-2 synthesis and secretion by the novel mechanism of receptor-mediated AP-1 induction.
近期分子证据表明,胸腺和外周T淋巴细胞会短暂和/或阶段性表达δ和κ阿片受体。由于药物治疗或应激通常会使阿片类物质水平升高,因此了解阿片类物质影响T淋巴细胞功能的机制非常重要。为此,我们构建并研究了一种表达克隆化δ阿片受体(DOR1)的T细胞系。特异性DOR1激动剂强啡肽与DOR1结合,通过与TCR-CD3和CD28发出的信号协同作用,增强了IL-2的分泌。利用报告基因构建体将强啡肽的这一作用定位到IL-2启动子的AP-1和NF-AT/AP-1结合位点。虽然DOR1信号传导增加了细胞内钙离子浓度([Ca2+]i),但强啡肽通过一种不依赖钙调神经磷酸酶且不同于细胞内钙离子浓度升高所产生效应的机制,增强了NF-AT/AP-1结合位点的转录活性。强啡肽还增加了AP-1转录因子复合物的积累,这表明DOR1通过增加NF-AT/AP-1转录因子的AP-1成分来增强IL-2的分泌。这些结果推动了对阿片类物质对淋巴细胞作用的分子理解,此外,还证明了通过受体介导的AP-1诱导这一新机制对IL-2合成和分泌的调节作用。